83 related articles for article (PubMed ID: 12844132)
21. Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis.
Tentolouris N; Boutati E; Karambakalis N; Perrea D; Tselepis AD; Tsoukala C; Kyriaki D; Lourida E; Anastasopoulou I; Karafoullidou A; Raptis SA; Katsilambros N
Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):6-12. PubMed ID: 15871845
[TBL] [Abstract][Full Text] [Related]
22. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism.
Granfors MT; Backman JT; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2004 Dec; 76(6):598-606. PubMed ID: 15592331
[TBL] [Abstract][Full Text] [Related]
23. Plasma concentrations of active simvastatin acid are increased by gemfibrozil.
Backman JT; Kyrklund C; Kivistö KT; Wang JS; Neuvonen PJ
Clin Pharmacol Ther; 2000 Aug; 68(2):122-9. PubMed ID: 10976543
[TBL] [Abstract][Full Text] [Related]
24. Gemfibrozil greatly increases plasma concentrations of cerivastatin.
Backman JT; Kyrklund C; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2002 Dec; 72(6):685-91. PubMed ID: 12496749
[TBL] [Abstract][Full Text] [Related]
25. A 3-way crossover study to evaluate the pharmacokinetic interaction between nateglinide and diclofenac in healthy volunteers.
Anderson DM; Shelley S; Crick N; Buraglio M
Int J Clin Pharmacol Ther; 2002 Oct; 40(10):457-64. PubMed ID: 12395978
[TBL] [Abstract][Full Text] [Related]
26. No effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers.
Anderson DM; Shelley S; Crick N; Buraglio M
J Clin Pharmacol; 2002 Dec; 42(12):1358-65. PubMed ID: 12463731
[TBL] [Abstract][Full Text] [Related]
27. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide.
Niemi M; Leathart JB; Neuvonen M; Backman JT; Daly AK; Neuvonen PJ
Clin Pharmacol Ther; 2003 Oct; 74(4):380-7. PubMed ID: 14534525
[TBL] [Abstract][Full Text] [Related]
28. Single-dose pharmacokinetics of nateglinide in subjects with hepatic cirrhosis.
Choudhury S; Hirschberg Y; Filipek R; Lasseter K; McLeod JF
J Clin Pharmacol; 2000 Jun; 40(6):634-40. PubMed ID: 10868314
[TBL] [Abstract][Full Text] [Related]
29. Orange juice substantially reduces the bioavailability of the beta-adrenergic-blocking agent celiprolol.
Lilja JJ; Juntti-Patinen L; Neuvonen PJ
Clin Pharmacol Ther; 2004 Mar; 75(3):184-90. PubMed ID: 15001969
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure.
Inoue T; Shibahara N; Miyagawa K; Itahana R; Izumi M; Nakanishi T; Takamitsu Y
Clin Nephrol; 2003 Aug; 60(2):90-5. PubMed ID: 12940610
[TBL] [Abstract][Full Text] [Related]
31. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations.
Kyrklund C; Backman JT; Kivistö KT; Neuvonen M; Laitila J; Neuvonen PJ
Clin Pharmacol Ther; 2000 Dec; 68(6):592-7. PubMed ID: 11180018
[TBL] [Abstract][Full Text] [Related]
32. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects.
Park JY; Kim KA; Kang MH; Kim SL; Shin JG
Clin Pharmacol Ther; 2004 Mar; 75(3):157-62. PubMed ID: 15001966
[TBL] [Abstract][Full Text] [Related]
33. No acute effect of nateglinide on postprandial lipid and lipoprotein responses in subjects at risk for type 2 diabetes.
Johanson EH; Jansson PA; Gustafson B; Sandqvist M; Taskinen MR; Smith U; Axelsen M
Diabetes Metab Res Rev; 2005; 21(4):376-81. PubMed ID: 15724236
[TBL] [Abstract][Full Text] [Related]
34. Influence of CYP2C9 and CYP2D6 polymorphisms on the pharmacokinetics of nateglinide in genotyped healthy volunteers.
Kirchheiner J; Meineke I; Müller G; Bauer S; Rohde W; Meisel C; Roots I; Brockmöller J
Clin Pharmacokinet; 2004; 43(4):267-78. PubMed ID: 15005635
[TBL] [Abstract][Full Text] [Related]
35. Nateglinide quantification in rabbit plasma by HPLC: optimization and application to pharmacokinetic study.
Sankalia JM; Sankalia MG; Sutariya VB; Mashru RC
J Pharm Biomed Anal; 2007 May; 44(1):196-204. PubMed ID: 17398055
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of nateglinide in renally impaired diabetic patients.
Devineni D; Walter YH; Smith HT; Lee JS; Prasad P; McLeod JF
J Clin Pharmacol; 2003 Feb; 43(2):163-70. PubMed ID: 12616669
[TBL] [Abstract][Full Text] [Related]
37. Rifampicin markedly decreases plasma concentration and hypnotic effect of brotizolam.
Ujiie Y; Fukasawa T; Yasui-Furukori N; Suzuki A; Tateishi T; Otani K
Ther Drug Monit; 2006 Jun; 28(3):299-302. PubMed ID: 16778710
[TBL] [Abstract][Full Text] [Related]
38. Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of buspirone.
Lamberg TS; Kivistö KT; Neuvonen PJ
Clin Pharmacol Ther; 1998 Jun; 63(6):640-5. PubMed ID: 9663178
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
Herman GA; Stevens C; Van Dyck K; Bergman A; Yi B; De Smet M; Snyder K; Hilliard D; Tanen M; Tanaka W; Wang AQ; Zeng W; Musson D; Winchell G; Davies MJ; Ramael S; Gottesdiener KM; Wagner JA
Clin Pharmacol Ther; 2005 Dec; 78(6):675-88. PubMed ID: 16338283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
